

September 12, 2023



**ANANDRATHI**  
INTERNATIONAL VENTURES(IFSC)  
Global Investments Simplified




# Update On Eli Lilly and Company



## Key highlights

- Eli Lilly and Company (LLY) Share Prices Maintain Strength Amidst Ongoing Market Volatility
- The company's products has been achieving strong double digit sales growth
- Lilly's Mounjaro showcases 6,000% sales growth potential

### Stock Price Trend: Eli Lilly and Company



### LLY Performance

CMP	595.56
YTD Change/%	229.72/62.79%
1Week Returns	6.90
1 Month Returns	12.73
52 Wk H (09/11/23)	598.16
52 Wk H (09/21/22)	296.32
Mkt Cap USD	565,362.2M

Source: Bloomberg (CMP as on 11<sup>th</sup> September, 2023)

## Eli Lilly's Stock Reaches Record Highs

Eli Lilly and Company discovers, develops, manufactures and sells pharmaceutical products for humans and animals. The company's products are sold in countries around the world. Eli Lilly products include neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology and animal health products. On September 11, 2023, the stock closed at \$595.56, reaching a 52-week high during the same trading session at \$598.16, marking a significant gain of approximately 6.90% within the past week.

Eli Lilly and Company (NYSE: LLY) witnessed a 2.31% increase in its stock price compared to 8th September 2023 closing price of 573.23. Furthermore, the company has observed a notable 5.82% rise in its stock price over the past five trading sessions.



In Q2 2023, the company reported a 28% revenue increase, driven by the growth of products like Mounjaro, Verzenio, Jardiance, and Taltz, alongside earning \$579.0 million from the sale of Baqsimi rights. Additionally, their breast cancer drug Verzenio achieved remarkable double-digit sales growth, rising from \$588 million in the same quarter last year to \$927 million, marking a substantial 57.7% increase in a thriving sector.

Lilly's standout drug, Mounjaro, which has been on the market for just a year, has seen remarkable growth. Sales soared from \$16 million to \$979 million in the latest quarter, marking an astonishing quarter-over-quarter sales increase of over 6,000%. Although initially approved for type 2 diabetes treatment, Mounjaro also led to substantial weight reductions compared to other treatments, marking a significant milestone as the first new class of FDA- approved diabetes drugs in the past decade

To conclude, Eli Lilly and Company has shown improved performance lately, with the stock now trading near its 50- day moving average and close to its 52-week high. The stock has seen impressive year-to-date growth of 229.72%, with a 62.79% increase and currently boasts a market capitalization of around \$565.36 billion (USD), reflecting its strong market performance."

*\* In the form of Un-sponsored Depository Receipts  
The update and data points are compiled from Bloomberg,  
NSE IFSC website along with other media reports*

**ANAND RATHI INTERNATIONAL VENTURES (IFSC) PRIVATE LIMITED**

Registered office: 6th Floor, Unit No. 634, Signature Tower, Building 13B, Road 1C, Zone 1, GIFT SEZ, GIFT City, Gandhi Nagar, Gujarat – 382355, India. CIN No.: U65999GJ2016PTC094915. SEBI Registration No.: INZ000292939 (INDIA INX Member Code-5064 | NSE IFSC Member Code-10048. Distributor (Capital Market Products and Services): 2023-24/0002.

For any complaints email at [Ifscgrievance@rathi.com](mailto:Ifscgrievance@rathi.com). Regulator: "International Financial Services Centre Authority (IFSCA)" <https://www.ifsc.gov.in>.

Disclaimer: Investment in Securities Market are subject to market risks. Read all the related documents carefully before investing. The securities quoted are only for exemplary and not recommendatory